Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

BMRN stock hub

BioMarin Pharmaceutical Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BMRNis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

10.4B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BMRN

In the news

Latest news · BMRN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E9.6

P25 12.3P50 18.4P75 33.1

Trailing P/E38.7

P25 14.9P50 23.2P75 38.5

ROE4.5

P25 -105.6P50 -46.5P75 -3.1

ROIC7.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BMRN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

266

Groups with data

Currency

USD

Showing 266 of 266 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001048477
Company name	BioMarin Pharmaceutical Inc.
Country	United States
Country code	US
Cusip	09061G101
Employees	3,221
Employees Change	181%
Employees Change Percent	5.95
Enterprise value	$9.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1999-07-23
Isin	US09061G1013
Last refreshed	2026-05-10
Market cap	$10.4B
Market cap category	Large-Cap
Price	$54.06
Price currency	USD
Rev Per Employee	1,006,617.82x
Sector	Healthcare
Sic	2834
Symbol	BMRN
Website	https://www.biomarin.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.57%
EV Earnings	35.97x
EV Sales Forward	2.49x
EV/EBIT	17.11x
EV/EBITDA	15.31x
EV/FCF	12.6x
EV/Sales	2.98x
FCF yield	7.34%
Forward P/E	9.58x
P/B ratio	1.68x
P/E ratio	38.71x
P/S ratio	3.22x
PE Ratio3 Y	60.93x
PE Ratio5 Y	150.55x
PEG ratio	0.34x
PS Forward	2.69x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	17.42%
EBITDA Margin	19.47%
FCF margin	23.66%
Gross margin	51.16%
Gross Profit	$1.7B
Gross Profit Growth	0.97%
Gross Profit Growth Q	-9.76%
Gross Profit Growth3 Y	17.97%
Gross Profit Growth5 Y	19.64%
Net Income	$268.7M
Net Income Growth	-48.7%
Net Income Growth Q	-43.17%
Net Income Growth Years	0%
Net Income Growth3 Y	55.4%
Net Income Growth5 Y	-19.5%
Pretax Margin	11.89%
Profit Margin	8.29%
Profit Per Employee	$83,434
Profitable Years	4
ROA	4.49
Roa5y	2.28
ROCE	7.24
ROE	4.48
Roe5y	3.83
ROIC	7.43
Roic5y	3.88

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-3.94%
Cagr15y	5.15%
Cagr1y	-8.87%
Cagr20y	7.35%
Cagr3y	-17.6%
Cagr5y	-7.02%
EPS Growth	-48.2
EPS Growth Q	-43.51
EPS Growth Years	0
EPS Growth3 Y	55.64
EPS Growth5 Y	-19.76
FCF Growth	22.89%
FCF Growth Q	26.71%
FCF Growth3 Y	192.02%
FCF Growth5 Y	46.21%
OCF Growth	24.85%
OCF Growth Q	26.52%
OCF Growth3 Y	81.01%
OCF Growth5 Y	32.5%
Revenue Growth	9.9x
Revenue Growth Q	2.83x
Revenue Growth Quarters	17x
Revenue Growth Years	4x
Revenue Growth3 Y	14.27x
Revenue Growth5 Y	11.94x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.41
Assets	$8.6B
Cash	$2.2B
Current Assets	$4.6B
Current Liabilities	$793.2M
Debt	$1.4B
Debt EBITDA	$2.24
Debt Equity	$0.23
Debt FCF	$1.88
Equity	$6.2B
Interest Coverage	24.56
Liabilities	$2.4B
Long Term Assets	$4B
Long Term Liabilities	$1.6B
Net Cash	$782.8M
Net Cash By Market Cap	$7.49
Net Cash Growth	16.78%
Net Debt EBITDA	$-1.24
Net Debt Equity	$-0.13
Net Debt FCF	$-1.02
Tangible Book Value	$5.8B
Tangible Book Value Per Share	$30.07
WACC	4.98

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.81
Inventory Turnover	1.24
Net Working Capital	$1.6B
Quick ratio	3.94
Working Capital	$3.8B
Working Capital Turnover	$0.97

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.86%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-33.09%
1Y total return	-8.87%
200-day SMA	56.27
3Y total return	-44.05%
50-day SMA	56.09
50-day SMA vs 200-day SMA	50under200
5Y total return	-30.49%
All Time High	151.8
All Time High Change	-64.38%
All Time High Date	2015-07-20
All Time Low	3.57
All Time Low Change	1,414.29%
All Time Low Date	2002-09-04
ATR	1.67
Beta	0.23
Beta1y	0.5
Beta2y	0.54
Ch YTD	-9.04
High	54.55
High52	66.28
High52 Date	2026-02-24
High52ch	-18.43%
Low	53.53
Low52	50.76
Low52 Date	2025-11-07
Low52ch	6.5%
Ma50ch	-3.62%
Premarket Change Percent	0.79
Premarket Price	$54.55
Premarket Volume	1,634
Price vs 200-day SMA	-3.92%
RSI	46.32
RSI Monthly	39.1
RSI Weekly	43.66
Sharpe ratio	-0.26x
Sortino ratio	-0.22
Total Return	-0.86%
Tr YTD	-9.04
Tr15y	112.42%
Tr1m	-3.84%
Tr3m	-7%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	18
Analyst Count Top	11
Analyst Price Target Top	$90.45
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$0.89
Earnings EPS Estimate Growth	-21.24
Earnings Revenue Estimate	754,593,800x
Earnings Revenue Estimate Growth	1.27x
Operating Income	$564.8M
Operating Income Growth	-8.85
Operating Income Growth Q	-38.38
Operating Income Growth3 Y	78.06
Operating margin	17.42
Price target	$89.61
Price Target Change	$65.76
Price Target Change Top	$67.31

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	192,153,823%
Float Percent	99.42%
Net Borrowing	850,000,000
Shares Insiders	0.49%
Shares Institutions	97.14%
Shares Out	193,270,028
Shares Qo Q	2.83%
Shares Yo Y	0.86%
Short Float	5.28%
Short Ratio	5.38
Short Shares	5.25

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$579.9M
Average Volume	1,751,505.4x
Bv Per Share	32.14
CAPEX	$-107.2M
Ch10y	-33.09
Ch15y	112.4
Ch1m	-3.84
Ch1y	-8.87
Ch20y	312.7
Ch3m	-7
Ch3y	-44.05
Ch5y	-30.49
Ch6m	5.05
Change	-0.11%
Change From Open	-0.17
Close	54.12
Days Gap	0.06
Depreciation Amortization	66,499,000
Dollar Volume	106,598,319.1
Earnings Date	2026-05-04
Earnings Time	amc
EBIT	$564.8M
EBITDA	$631.3M
EPS	$1.4
F Score	5
FCF	$767.1M
FCF EV Yield	7.94x
FCF Per Share	$3.97
Financing CF	809,552,000
Fiscal Year End	December
Founded	1,996
Goodwill	196,199,000
Graham Number	31.77957
Graham Upside	-41.21
Income Tax	$116.9M
Investing CF	339,524,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-04
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Lynch Fair Value	$6.98
Lynch Upside	-87.08
Ma150	56.06
Ma150ch	-3.57%
Ma20	54.3
Ma20ch	-0.44%
Net CF	2,023,632,000
Next Earnings Date	2026-08-03
Open	54.15
Optionable	Yes
P FCF Ratio	13.62
P OCF Ratio	11.95
Position In Range	51.96
Post Close	54.06
Postmarket Change Percent	1.18
Postmarket Price	$54.7
Ppne	958,071,000
Pre Close	54.12
Price Date	2026-05-08
Price EBITDA	$16.55
Ptbv Ratio	1.8
Relative Volume	1.13x
Revenue	3,242,316,000x
SBC By Revenue	5.77x
Share Based Comp	187,167,000
Tax By Revenue	3.6x
Tax Rate	30.3%
Tr20y	312.67%
Tr6m	5.05%
Us State	California
Volume	1,971,852
Z Score	3.94

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BMRN pay a dividend?

Capital-return profile for this ticker.

Performance

BMRN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BMRN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+97.1%

Float: +99.4% of shares outstanding

Insider ownership

+0.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BMRN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.3

Neutral momentum band

Price vs 200-day MA

-3.9%

50/200-day relationship not available

Beta (5Y)

0.23

Less volatile than the market

Sharpe ratio

-0.26

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BMRN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BMRN stock rating?

BioMarin Pharmaceutical Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BMRN analysis?

The full report lives at /stocks/BMRN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BMRN?

The latest report frames BMRN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BMRN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.